Erythropoietin (EPO)
Also known as: EPO, Erythropoietin, Epoetin, rHuEPO
EPO | Red Blood Cell Stimulating Hormone
Overview
Erythropoietin (EPO) is an essential glycoprotein hormone that stimulates red blood cell production. Naturally produced by the kidneys in response to low oxygen levels, recombinant human EPO is FDA-approved for treating anemia in chronic kidney disease and chemotherapy patients. EPO binding to receptors on bone marrow cells promotes survival and maturation of red blood cell precursors, increasing oxygen-carrying capacity. Due to performance-enhancing effects, it is banned in competitive sports.
Key benefits
- Stimulates red blood cell production
- Increases oxygen-carrying capacity
- FDA-approved for anemia treatment
- Improves endurance capacity
- Supports patients with chronic kidney disease
- Helps chemotherapy-induced anemia
- Well-characterized mechanism of action
- Extensively studied safety profile
Mechanism of action
EPO binds to erythropoietin receptors (EPOR) on erythroid progenitor cells in bone marrow, activating three interconnected signaling pathways: JAK2/STAT5, PI3K/AKT, and RAS/MAPK. This promotes survival of red blood cell precursors by protecting them from apoptosis, accelerates proliferation and differentiation of erythroid cells, and increases hemoglobin production. Under hypoxic stress, endogenous EPO production can increase up to 1000-fold, demonstrating the body's powerful oxygen-sensing regulatory system.
Molecular data
- Type
- Glycoprotein hormone
- Half-life
- 4-12 hours (IV), ~25 hours (SubQ)
Indications
What the research community uses this compound for, with self-reported effectiveness.
Medical Indications (FDA-Approved)
Performance (Banned in Sports)
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 50-100 IU/kg | 3x weekly | — |
| — | 150-300 IU/kg | 3x weekly | — |
| — | Individualized | 1-3x weekly | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Injection site reactions
- Headache
- Hypertension
- Joint pain
- Flu-like symptoms
Rare side effects
- Pure red cell aplasia (very rare)
- Thromboembolic events
- Stroke
- Myocardial infarction
- Tumor progression (theoretical)
Contraindications
- Uncontrolled hypertension
- Pure red cell aplasia history
- Hemoglobin >12 g/dL (increased cardiovascular risk)
- Active malignancy (relative contraindication)
Monitoring
- Regular hemoglobin monitoring essential
- Blood pressure monitoring
- Iron status assessment
- Keep hemoglobin below 11-12 g/dL to reduce risks